The Pharmer's Market
A group of researchers — Ragu Bharadwaj, Eric von Hippel and Fiona Murray at MIT's Sloan School and Peter Coles at Harvard Business School — have spearheaded development of a prediction market at Crowdcast.com that focuses on questions relating to the pharmaceuticals industry.The current questions on which individuals with pharmaceutical knowledge are invited to weigh in, deal with drug candidates for breast cancer treatment:
- Will AMG 706 make it through Phase 2 Trials to Phase 3 by July 2010?
- Will ABT-869 make it through Phase 2 trials to Phase 3 by March 31, 2010?
When will Phase 3 Trials for breast cancer be announced? - Will AZD2281 make it through Phase 2 trials to Phase 3 by March 31, 2010?
When will Phase 3 Trials for breast cancer be announced? - Will BIBW 2992 make it through Phase 2 trials to Phase 3 by March 31, 2010?
When will Phase 3 Trials for breast cancer be announced? - Will BMS-599626 make it through Phase 1 trials to Phase 2 by March 31, 2010?
When will Phase 2 Trials be announced? - Will BMS-690514 make it through Phase 1 trials to Phase 2 by October 2010?
- Will Cediranib make it through Phase 2 trials to Phase 3 by Jan 1, 2010?
When will Phase 3 Trials for breast cancer be announced? - Will Dasatinib make it to Phase 3 trials by July 1, 2010?
- Will Lonaprisan make it through Phase 2 trials to Phase 3 by Jan 1, 2010?
When will Phase 3 Trials be announced?
For more about the context of hugely expensive drug development into which the Pharmer's Market fits, you can read an article by Natasha Singer published in today's New York Times.
Labels: Prediction markets
posted by Karen Nelson @ 11:38 PM
<< Home